Stephen M. Kanovsky net worth and biography

Stephen Kanovsky Biography and Net Worth

Director of NeoGenomics

Mr. Kanovsky recently retired as Deputy General Counsel of GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics. In addition to pharmaceutical research experience and private practice legal experience, Mr. Kanovsky has over 25 years of legal experience in the global life sciences and biotechnology industry. Mr. Kanovsky earned his bachelor's degree in Chemistry and Biophysics from the University of Pennsylvania. He subsequently graduated from Temple University's School of Pharmacy with a master's degree in Pharmacology and Temple University's School of Law with a juris doctorate degree. Mr. Kanovsky also holds a master's degree in business administration from Saint Joseph University's Haub School of Business. He has been an Adjunct Professor for Saint Joseph’s MBA programs. He is also a co-editor of and contributing author to the Food and Drug Law Institute’s “A Practical Guide to FDA’s Food and Drug Law and Regulation” (Seventh Edition, 2020).

What is Stephen M. Kanovsky's net worth?: The estimated net worth of Stephen M. Kanovsky is at least $466.25 thousand as of May 7th, 2025. Kanovsky owns 40,090 shares of NeoGenomics stock worth more than $466,247 as of December 17th. This net worth evaluation does not reflect any other investments that Kanovsky may own. Learn More about Stephen M. Kanovsky's net worth.
How do I contact Stephen M. Kanovsky?: The corporate mailing address for Kanovsky and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Stephen M. Kanovsky's contact information.
Has Stephen M. Kanovsky been buying or selling shares of NeoGenomics?: Stephen M. Kanovsky has not been actively trading shares of NeoGenomics during the last ninety days. Most recently, on Wednesday, May 7th, Stephen M. Kanovsky bought 4,000 shares of NeoGenomics stock. The stock was acquired at an average cost of $7.78 per share, with a total value of $31,120.00. Following the completion of the transaction, the director now directly owns 40,090 shares of the company's stock, valued at $311,900.20. Learn More on Stephen M. Kanovsky's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Stephen Kanovsky (Director), Michael Kelly (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), David Perez (Director), Jeffrey Sherman (CFO), Robert Shovlin (Insider), Warren Stone (President and Chief Operating Officer), Lynn Tetrault (Director), and Anthony Zook (CEO). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, NeoGenomics insiders bought shares 7 times. They purchased a total of 70,600 shares worth more than $550,438.00. During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 20,916 shares worth more than $250,992.00. The most recent insider tranaction occured on November, 25th when EVP Alicia C Olivo sold 20,916 shares worth more than $250,992.00. Insiders at NeoGenomics own 2.4% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/25/2025.

Stephen M. Kanovsky Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/7/2025	Buy	4,000	$7.78	$31,120.00	40,090

Stephen M. Kanovsky Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $11.63

$11.46

$11.72

50 Day Range

MA: $10.79

$8.97

$12.34

2 Week Range

Now: $11.63

$4.72

$19.11

Volume

1,578,532 shs

Average Volume

2,345,460 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6